Valerio Therapeutics Provides an Update on Its Business and Presents Its Financial Results for the First Half of 2026
Business Wire•07/10/2026•02:21 ET
1
Key Highlights
- ➤Etherna acquisition completion scheduled for 8 October 2026
- ➤H1 turnover €3.102 million, versus €126,000 in 2025
- ➤H1 consolidated net loss €2.361 million, versus €208,000 loss
- ➤Cash €656,000 at 30 June; resources cover at least 12 months
- ➤€40.25 million capital increase issued 68,220,333 shares at €0.59
Expert Statements
Gilles Besin, Chief Executive Officer of Valerio Therapeutics
“The first half of 2026 marked a decisive milestone in the consolidation of our strategic refocusing and in the transformation of Valerio Therapeutics. The operational launch of InVimmune, the strengthening of our partnerships, the signing of the definitive agreement for the acquisition of Etherna and the governance transition demonstrate our ability to implement our roadmap with determination, consistency and discipline. These complementary advances strengthen our positioning and open up new prospects for therapeutic development. We now have a solid foundation on which to accelerate the development of our targeted RNA delivery platform, deepen scientific and operational synergies within the Group, and advance our proprietary programmes towards key milestones that are likely to create sustainable value for our patients, partners and shareholders.”
Valerio Therapeutics Provides an Update on Its Business and Presents Its Financial Results for the First Half of 2026
* Operational launch of InVimmune, a subsidiary dedicated to differentiated approaches to in vivo cell therapy, with a first indication announced in oncology.
Get started
Create a free account to read the full story.